dc.contributor.author | Minchom, A | |
dc.contributor.author | Yuan, W | |
dc.contributor.author | Crespo, M | |
dc.contributor.author | Gurel, B | |
dc.contributor.author | Figueiredo, I | |
dc.contributor.author | Wotherspoon, A | |
dc.contributor.author | Miranda, S | |
dc.contributor.author | Riisnaes, R | |
dc.contributor.author | Ferreira, A | |
dc.contributor.author | Bertan, C | |
dc.contributor.author | Pereira, R | |
dc.contributor.author | Clarke, M | |
dc.contributor.author | Baker, C | |
dc.contributor.author | Ang, JE | |
dc.contributor.author | Fotiadis, N | |
dc.contributor.author | Tunariu, N | |
dc.contributor.author | Carreira, S | |
dc.contributor.author | Popat, S | |
dc.contributor.author | O'Brien, M | |
dc.contributor.author | Banerji, U | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Lopez, J | |
dc.date.accessioned | 2020-04-14T15:27:54Z | |
dc.date.issued | 2020-03-01 | |
dc.identifier.citation | Journal for immunotherapy of cancer, 2020, 8 (1) | |
dc.identifier.issn | 2051-1426 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3592 | |
dc.identifier.eissn | 2051-1426 | |
dc.identifier.doi | 10.1136/jitc-2020-000713 | |
dc.description.abstract | BACKGROUND: This case represents an exceptional response to pembrolizumab in a patient with epithelioid mesothelioma with a further response on rechallenge. CASE PRESENTATION: A 77-year-old woman with advanced epithelioid mesothelioma extensively pretreated with chemotherapy demonstrated a prolonged response of 45 months to 52 cycles of pembrolizumab. On rechallenge with pembrolizumab, further disease stability was achieved. Serial biopsies and analysis by immunohistochemistry and immunofluorescence demonstrated marked immune infiltration and documented the emergency of markers of immune exhaustion. Whole exome sequencing demonstrated a reduction in tumor mutational burden consistent with subclone elimination by immune checkpoint inhibitor (CPI) therapy. The relapse biopsy had missense mutation in BTN2A1. CONCLUSION: This case supports rechallenge of programme death receptor 1 inhibitor in cases of previous CPI sensitivity and gives molecular insights. | |
dc.format | Print | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | BMJ PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
dc.subject | Humans | |
dc.subject | Mesothelioma | |
dc.subject | Lung Neoplasms | |
dc.subject | Pleural Neoplasms | |
dc.subject | Prognosis | |
dc.subject | Retreatment | |
dc.subject | Aged | |
dc.subject | Female | |
dc.subject | Antibodies, Monoclonal, Humanized | |
dc.subject | Biomarkers, Tumor | |
dc.subject | B7-H1 Antigen | |
dc.subject | Mesothelioma, Malignant | |
dc.title | Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-02-05 | |
rioxxterms.versionofrecord | 10.1136/jitc-2020-000713 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
rioxxterms.licenseref.startdate | 2020-03 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Journal for immunotherapy of cancer | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine (de Bono Prostate) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Treatment of thoracic tumours/Treatment of thoracic tumours (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 8 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (de Bono Prostate) | |
icr.researchteam | Cancer Biomarkers | |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | |
icr.researchteam | Prostate Cancer Targeted Therapy Group | |
icr.researchteam | Thoracic Oncology | |
icr.researchteam | Treatment of thoracic tumours | |
dc.contributor.icrauthor | Minchom, Anna | |
dc.contributor.icrauthor | Gurel, Bora | |
dc.contributor.icrauthor | Miranda, Susana | |
dc.contributor.icrauthor | Pereira, Ana Rita | |
dc.contributor.icrauthor | Carreira, Suzanne | |
dc.contributor.icrauthor | Banerji, Udai | |
dc.contributor.icrauthor | De Bono, Johann | |